Literature DB >> 9824096

Analysis of cell cycle regulators: p16INK4A, pRb, and CDK4 in low- and high-grade meningiomas.

J Y Tse1, H K Ng, K W Lo, E Y Chong, P Y Lam, E K Ng, W S Poon, D P Huang.   

Abstract

Abnormalities in the p16INK4A, CDK4, and Rb genes, which regulate transition through G1 phase of the cell cycle, have been implicated in the progression of diverse types of cancer. To evaluate the involvement of p16INK4A, CDK4, and Rb in the tumorigenesis of meningiomas, the status of these genes or gene products were examined. The genetic alteration of the p16INK4A gene was examined by homozygous deletions and by mutation analysis. The methylation status of the p16INK4A was determined by Southern blotting. Neither homozygous deletions nor point mutations of the p16INK4A gene were observed in any of the 23 meningiomas. Partial rather than complete methylation of the p16INK4A gene at SacII or SmaI sites was shown in five (23.8%) meningiomas. The methylation status of the p16INK4A gene was not consistently associated with the expression of p16INK4A in meningiomas. These results suggest that the true relationship between methylation and expression of p16INK4A may be obscured in a complex manner by various mechanisms that regulate p16INK4A expression. Aberrant expressions of pRb and CDK4 were not observed in any of the meningiomas we examined, indicating that abnormalities of the pRb and CDK4 appear to be rare in meningiomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824096     DOI: 10.1016/s0046-8177(98)90246-5

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  7 in total

1.  Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse.

Authors:  Michel Kalamarides; Michiko Niwa-Kawakita; Hélène Leblois; Vincent Abramowski; Michel Perricaudet; Anne Janin; Gilles Thomas; David H Gutmann; Marco Giovannini
Journal:  Genes Dev       Date:  2002-05-01       Impact factor: 11.361

2.  Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.

Authors:  J Boström; B Meyer-Puttlitz; M Wolter; B Blaschke; R G Weber; P Lichter; K Ichimura; V P Collins; G Reifenberger
Journal:  Am J Pathol       Date:  2001-08       Impact factor: 4.307

3.  Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.

Authors:  M Simon; T W Park; G Köster; R Mahlberg; M Hackenbroch; J Boström; T Löning; J Schramm
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

4.  Molecular characterization of human meningiomas by gene expression profiling using high-density oligonucleotide microarrays.

Authors:  Mark A Watson; David H Gutmann; Kelly Peterson; Michael R Chicoine; Bette K Kleinschmidt-DeMasters; Henry G Brown; Arie Perry
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

5.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

6.  Methylation and Expression of Retinoblastoma and Transforming Growth Factor-β1 Genes in Epstein-Barr Virus-Associated and -Negative Gastric Carcinomas.

Authors:  Xia Liu; Xiuming Tang; Shaoyan Zhang; Yun Wang; Xiaofeng Wang; Chengquan Zhao; Bing Luo
Journal:  Gastroenterol Res Pract       Date:  2012-09-12       Impact factor: 2.260

7.  The effects of palbociclib in combination with radiation in preclinical models of aggressive meningioma.

Authors:  Craig Horbinski; Guifa Xi; Yufen Wang; Rintaro Hashizume; Mahesh Gopalakrishnan; Joanna J Phillips; Peter Houghton; Charles D James; John A Kalapurakal
Journal:  Neurooncol Adv       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.